However, both AML and MDS are heterogeneous diseases, and DLX5 methylation pattern were not analyzed in single tumor cell population such as CD34+ cell population, leading to a huge difference of DLX5 methylation in patients with AML and MDS. The gene discussed is CD34; the disease is neoplasm.